Concord Drugs (BOM:538965) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
64 GF Score
Price ₹81.92
GF Value ₹64.35
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Concord Drugs Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BOM:538965
64GF Score
Concord Drugs Ltd BOM:538965
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹81.92 is trading 27.3% above its estimated GF Value™ of ₹64.35. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Dividends Received:
  • GF Value™: ₹64.35 vs. price of ₹81.92 (27.3% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
64GF Score

Get the complete analysis for BOM:538965

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹81.92
Price
₹64.35
GF Value